Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AZN | London | GBP | Real-time | |
3LAZ | London | GBP | Real-time | |
3SAZ | London | GBP | Real-time | |
AZNl | BATS Europe | GBP | Delayed | |
AZNs | BATS Europe | SEK | Delayed | |
AZNCF | OTC Markets | USD | Delayed | |
AZN | NASDAQ | USD | Real-time | |
AZNN | BIVA | MXN | Delayed | |
AZNN | Mexico | MXN | Delayed | |
AZN | Stockholm | SEK | Real-time | |
AZNPy | Frankfurt | EUR | Delayed | |
AZNPy | TradeGate | EUR | Delayed | |
AZN | TradeGate | EUR | Delayed | |
AZN | Frankfurt | EUR | Delayed | |
AZN | Xetra | EUR | Delayed | |
AZNm | Buenos Aires | ARS | Delayed | |
A1ZN34 | B3 | BRL | Delayed | |
AZNA | Vienna | EUR | Real-time |
AstraZeneca PLC reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was USD 482 million compared to USD 341 million a year ago. Revenue was USD 12,938 million compared to USD 11,416 million a year ago. Net income was USD 1,927 million compared to USD 1,818 million a year ago. Basic earnings per share from continuing operations was USD 1.24 compared to USD 1.17 a year ago. Diluted earnings per share from continuing operations was USD 1.24 compared to USD 1.17 a year ago.For the six months, sales was USD 939 million compared to USD 627 million a year ago. Revenue was USD 25,617 million compared to USD 22,295 million a year ago. Net income was USD 4,106 million compared to USD 3,621 million a year ago. Basic earnings per share from continuing operations was USD 2.34 compared to USD 2.65 a year ago. Diluted earnings per share from continuing operations was USD 2.32 compared to USD 2.63 a year ago.
Period Ending: | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
---|---|---|---|---|
Total Revenue | 12938 | 12679 | 12024 | 11492 |
Gross Profit | 10771 | 10481 | 9729 | 9437 |
Operating Income | 2900 | 3310 | 2034 | 2533 |
Net Income | 1927 | 2179 | 960 | 1374 |
Period Ending: | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
---|---|---|---|---|
Total Assets | 104340 | 102293 | 101119 | 96086 |
Total Liabilities | 64742 | 64792 | 61953 | 58865 |
Total Equity | 39598 | 37501 | 39166 | 37221 |
Period Ending: | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 3085 | 2486 | 2380 | 3114 |
Cash From Investing Activities | -2872 | -2413 | -1077 | -1221 |
Cash From Financing Activities | -1222 | 2028 | -291 | -2726 |
Net Change in Cash | -1015 | 2055 | 1018 | -852 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review